sitryx-no-molecule-no-i-wb.png
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
10 avr. 2024 07h00 HE | Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Vivtex logo.png
Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
18 janv. 2024 09h00 HE | Vivtex
Cambridge/Boston, MA, USA – 18th January 2024. Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins,...
sitryx-no-molecule-no-i-wb.png
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
04 janv. 2024 02h00 HE | Sitryx Therapeutics
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...
MC2_TherapeuticsScreenMC2_logo.jpg
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 07h00 HE | MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2_TherapeuticsScreenMC2_logo.jpg
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
07 déc. 2023 02h00 HE | MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2_TherapeuticsScreenMC2_logo.jpg
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 07h00 HE | MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2_TherapeuticsScreenMC2_logo.jpg
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
23 nov. 2023 02h00 HE | MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
Global Ankylosing Spondylitis Market
Global Ankylosing Spondylitis Market is Projected to Reach $7.29 Billion by 2027: Leading Players Pfizer, AbbVie, and Novartis Drive Advances in Treatment Options
12 oct. 2023 07h03 HE | Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ankylosing spondylitis...
Global Immune Thrombocytopenia Market
Immune Thrombocytopenia Market Set to Reach USD 3.39 Billion by 2031: Key Trends and Advancements
10 oct. 2023 04h28 HE | Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Immune Thrombocytopenia Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global immune...
Invea Logo.jpg
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
06 déc. 2022 08h10 HE | Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...